Apigenin inhibits pancreatic stellate cell activity in pancreatitis

Amy A. Mrazek, Laura J. Porro, Vandanajay Bhatia, Miriam Falzon, Heidi Spratt, Jia Zhou, Celia Chao, Mark Hellmich

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. Materials and methods Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of human pancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. Results After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. Conclusions These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.

Original languageEnglish (US)
Pages (from-to)8-16
Number of pages9
JournalJournal of Surgical Research
Volume196
Issue number1
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Pancreatic Stellate Cells
Apigenin
Pancreatitis
Chronic Pancreatitis
Fibrosis
Parathyroid Hormone-Related Protein
Fibronectins
Apoptosis
Ceruletide
Extracellular Matrix Proteins
Wounds and Injuries
Proliferating Cell Nuclear Antigen
Proxy
Transforming Growth Factor beta
Reverse Transcription
Pancreas
Interleukin-6
Patient Care
Necrosis
Collagen

Keywords

  • Apigenin
  • Chronic pancreatitis
  • Pancreatic stellate cells
  • Parathyroid hormone-related protein

ASJC Scopus subject areas

  • Surgery

Cite this

Apigenin inhibits pancreatic stellate cell activity in pancreatitis. / Mrazek, Amy A.; Porro, Laura J.; Bhatia, Vandanajay; Falzon, Miriam; Spratt, Heidi; Zhou, Jia; Chao, Celia; Hellmich, Mark.

In: Journal of Surgical Research, Vol. 196, No. 1, 01.06.2015, p. 8-16.

Research output: Contribution to journalArticle

@article{2d103619282b4814a4b5dd03f62502ff,
title = "Apigenin inhibits pancreatic stellate cell activity in pancreatitis",
abstract = "Background Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. Materials and methods Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of human pancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. Results After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. Conclusions These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.",
keywords = "Apigenin, Chronic pancreatitis, Pancreatic stellate cells, Parathyroid hormone-related protein",
author = "Mrazek, {Amy A.} and Porro, {Laura J.} and Vandanajay Bhatia and Miriam Falzon and Heidi Spratt and Jia Zhou and Celia Chao and Mark Hellmich",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jss.2015.02.032",
language = "English (US)",
volume = "196",
pages = "8--16",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Apigenin inhibits pancreatic stellate cell activity in pancreatitis

AU - Mrazek, Amy A.

AU - Porro, Laura J.

AU - Bhatia, Vandanajay

AU - Falzon, Miriam

AU - Spratt, Heidi

AU - Zhou, Jia

AU - Chao, Celia

AU - Hellmich, Mark

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Background Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. Materials and methods Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of human pancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. Results After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. Conclusions These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.

AB - Background Chronic pancreatitis (CP) is characterized by recurrent pancreatic injury, resulting in inflammation, necrosis, and fibrosis. There are currently no drugs limiting pancreatic fibrosis associated with CP, and there is a definite need to fill this void in patient care. Materials and methods Pancreatitis was induced in C57/BL6 mice using supraphysiologic doses of cerulein, and apigenin treatment (once daily, 50 μg per mouse by oral gavage) was initiated 1 wk into the recurrent acute pancreatitis (RAP) protocol. Pancreata were harvested after 4 wk of RAP. Immunostaining with fibronectin antibody was used to quantify the extent of pancreatic fibrosis. To assess how apigenin may decrease organ fibrosis, we evaluated the effect of apigenin on the proliferation and apoptosis of human pancreatic stellate cells (PSCs) in vitro. Finally, we assessed apigenin's effect on the gene expression in PSCs stimulated with parathyroid hormone-related protein, a profibrotic and proinflammatory mediator of pancreatitis, using reverse transcription-polymerase chain reaction. Results After 4 wk of RAP, apigenin significantly reduced the fibrotic response to injury while preserving acinar units. Apigenin inhibited viability and induced apoptosis of PSCs in a time- and dose-dependent manner. Finally, apigenin reduced parathyroid hormone-related protein-stimulated increases in the PSC messenger RNA expression levels of extracellular matrix proteins collagen 1A1 and fibronectin, proliferating cell nuclear antigen, transforming growth factor-beta, and interleukin-6. Conclusions These in vivo and in vitro studies provide novel insights regarding apigenin's mechanism(s) of action in reducing the severity of RAP. Additional preclinical testing of apigenin analogs is warranted to develop a therapeutic agent for patients at risk for CP.

KW - Apigenin

KW - Chronic pancreatitis

KW - Pancreatic stellate cells

KW - Parathyroid hormone-related protein

UR - http://www.scopus.com/inward/record.url?scp=84929287440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929287440&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2015.02.032

DO - 10.1016/j.jss.2015.02.032

M3 - Article

C2 - 25799526

AN - SCOPUS:84929287440

VL - 196

SP - 8

EP - 16

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -